{
  "question_stem": {
    "en": "An investigator is conducting a randomized, double-blind, placebo-controlled clinical trial of a new drug for the treatment of peripheral neuropathy in adults with multiple myeloma (MM). One hundred fifty patients with MM are enrolled in the trial and randomized to receive either the new drug (n = 75) or placebo (n = 75). Trial protocol requires that patients in both groups take 1 pill per day and keep a pain diary. After 3 months of treatment, each patient is interviewed, and the pain diaries are reviewed; 9 patients taking the new drug and 3 patients taking placebo did not take the pills as instructed. The investigator decides to conduct an intention-to-treat analysis of the study data.",
    "zh": "一位研究者正在进行一项随机、双盲、安慰剂对照的临床试验，旨在研究一种治疗多发性骨髓瘤 (MM) 成人周围神经病变的药物。150 名 MM 患者入组试验，并被随机分配接受新药 (n = 75) 或安慰剂 (n = 75)。试验方案要求两组患者每天服用 1 片药，并保留疼痛日记。治疗 3 个月后，对每位患者进行访谈，并审查疼痛日记；9 名服用新药的患者和 3 名服用安慰剂的患者未按指示服药。研究者决定对研究数据进行意向性治疗分析。"
  },
  "question": {
    "en": "Which of the following best describes how the data pertaining to all patients who did not adhere to protocol should be treated?",
    "zh": "以下哪项最能描述应如何处理所有未遵守方案的患者的相关数据？"
  },
  "options": {
    "A": {
      "en": "Conduct separate analyses of the 12 nonadherent patients and the 138 adherent patients",
      "zh": "对 12 名不依从患者和 138 名依从患者进行单独分析"
    },
    "B": {
      "en": "Exclude all 12 nonadherent patients from analysis",
      "zh": "从分析中排除所有 12 名不依从患者"
    },
    "C": {
      "en": "Exclude the 3 nonadherent patients in the group taking placebo from analysis",
      "zh": "从分析中排除安慰剂组中的 3 名不依从患者"
    },
    "D": {
      "en": "Exclude the 9 nonadherent patients in the group taking the new drug from analysis",
      "zh": "从分析中排除服用新药组中的 9 名不依从患者"
    },
    "E": {
      "en": "Keep all 12 nonadherent patients in their respective groups for analysis",
      "zh": "将所有 12 名不依从患者保留在其各自的组中进行分析"
    }
  },
  "correct_answer": "E",
  "explanation": {
    "en": "An **intention-to-treat (ITT)** analysis compares treatment groups in a randomized trial by **including all subjects** as initially allocated after randomization **regardless of what happens** during the study period. The rationale is that if subjects have such a poor treatment response (or are so inconvenienced by treatment administration or side effects) as to not follow protocol specifications or drop out of the study, then their outcomes should be attributed to that intervention (ie, nonadherence is related to the practical benefits of treatment). ITT analysis also helps avoid the effects of attrition (eg, loss to follow-up, dropout) and crossover (eg, switching to another assigned intervention), which may disrupt the benefit of randomization and introduce bias in the estimation of the effect of the intervention.\n\nITT analysis may lead to a more **conservative estimate** of the effect of the intervention. If attrition or crossover is significant, ITT analysis may be less likely to identify a statistically significant difference between treatments (ie, shift toward the null hypothesis). However, results will reflect the **expected effect of the intervention in a practical clinical setting**.\n\n**(Choices A, C, and D)** In accordance with ITT analysis, the investigator in this case should keep the 12 nonadherent patients in their respective groups for analysis.\n\n**(Choice B)** An analysis that includes only those patients who strictly adhered to a research protocol (ie, excluding all nonadherent patients from analysis) follows a per-protocol (PP) principle. In PP analysis, the benefit of randomization can be lost with significant subject attrition (eg, sicker subjects selectively dropping out, introducing bias). PP analysis can also overestimate the effect of the intervention in a practical clinical setting, particularly when the treatment is somehow aversive to patients.\n\n**Educational objective:**\nIntention-to-treat analysis includes each subject in their initial randomization group even if subjects stop the intervention or shift to a different intervention. This approach tends to provide a conservative but more valid estimate of the intervention effect in real-world scenarios (ie, clinical settings).",
    "zh": "**意向性治疗 (ITT)** 分析通过在随机试验中**纳入所有受试者**（无论研究期间发生什么情况），来比较治疗组。其基本原理是，如果受试者的治疗反应很差（或者因治疗给药或副作用而感到不便），以至于不遵守方案规范或退出研究，那么他们的结局应归因于该干预措施（即，不依从性与治疗的实际益处相关）。ITT 分析还有助于避免损耗（例如，失访、退出）和交叉（例如，切换到另一种指定的干预措施）的影响，这些影响可能会破坏随机化的益处，并在估计干预措施的影响时引入偏倚。\n\nITT 分析可能会导致对干预措施的**保守估计**。如果损耗或交叉有意义，ITT 分析可能不太可能识别出治疗之间的统计学显着差异（即，向零假设方向移动）。然而，结果将反映**干预措施在实际临床环境中的预期效果**。\n\n**(选项 A、C 和 D)** 按照 ITT 分析，本例中的研究者应将 12 名不依从患者保留在其各自的组中进行分析。\n\n**(选项 B)** 仅包括严格遵守研究方案的患者的分析（即，从分析中排除所有不依从患者）遵循了方案内 (PP) 原则。在 PP 分析中，随机化的好处可能会因受试者的大量损耗而丧失（例如，较重的患者选择性退出，从而引入偏倚）。PP 分析也可能高估干预措施在实际临床环境中的效果，尤其是在治疗对患者来说具有某种程度的厌恶感时。\n\n**教育目标：**\n意向性治疗分析将每位受试者纳入其最初的随机分组，即使受试者停止干预或转向不同的干预措施。这种方法倾向于在现实世界的情景（即临床环境）中提供对干预效果的保守但更有效的估计。"
  },
  "summary": {
    "en": "This question tests the understanding of intention-to-treat (ITT) analysis in clinical trials, specifically how to handle patients who do not adhere to the study protocol. ITT analysis is a critical concept in clinical research methodology.\n\nThe key to solving this question is recognizing that ITT analysis requires including all patients in their originally assigned groups, regardless of adherence. This approach preserves the benefits of randomization and provides a more realistic estimate of treatment effectiveness in real-world settings.",
    "zh": "本题考察了对临床试验中意向性治疗 (ITT) 分析的理解，特别是如何处理不遵守研究方案的患者。ITT 分析是临床研究方法学中的一个关键概念。\n\n解决此问题的关键是认识到 ITT 分析要求将所有患者纳入其最初分配的组中，无论其依从性如何。这种方法保留了随机化的好处，并提供了对真实世界环境中治疗有效性的更现实的估计。"
  },
  "tags": "Intention-to-treat analysis; Clinical trials; Research methodology; Bias; Randomization; Per-protocol analysis",
  "category": "Bio",
  "question_id": "19406",
  "has_exhibits": false,
  "exhibit_count": 0,
  "exhibit_files": [],
  "folder_path": "C:\\Datas\\usmle\\step1\\clip\\Bio & Statistics 23\\19406",
  "extracted_at": "2025-11-05T11:13:45.934492",
  "extraction_config": {
    "temperature": 0.1,
    "top_k": 1,
    "prompt_strategy": "standard"
  },
  "translated_at": "2025-11-07T16:22:39.296288",
  "translation_model": "gemini-2.0-flash-lite",
  "embedding_model": "models/embedding-001",
  "embedding_dimension": 768
}